Loading
Cancer drugs are often prescribed outside their approved use based on hope or small studies. Capturing outcomes of these uses would reveal which ones fail so they can be stopped.
Off-label use is common in oncology, particularly for targeted agents matched to molecular alterations in other cancers. Structured outcome capture at the point of off-label prescribing (indication, rationale, response, duration, toxicity) through a simple registry, as the Dutch DRUP trial and the US TAPUR study do within trial frameworks, but extended to routine practice, would document failures that are otherwise invisible.
Shares Real-world evidence, Failures are hidden, Weak real-world evidence and registries.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Tumour-agnostic (tissue-agnostic) approval, Real-world evidence, Weak real-world evidence and registries.
Shares Payers cover off-label combinations only inside registry-randomised trials, Real-world evidence, Weak real-world evidence and registries.
Shares Payers cover off-label combinations only inside registry-randomised trials, Real-world evidence.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Real-world evidence, Weak real-world evidence and registries.